Dysmenorrhea Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The market is segmented by Treatment Type (Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Hormonal Therapy), Type, and Geography.

Market Snapshot

Dysmenorrhea Treatment Market 1
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 8.1 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The dysmenorrhea treatment market is expected to register a CAGR of 8.1% during the forecast period. Dysmenorrhea, also known as menstrual cramps, is cramping or throbbing pains in the lower abdomen. Most of the women experience dysmenorrhea just before and during their menstrual periods. Dysmenorrhea is of two types, namely primary and secondary dysmenorrhea. Prostaglandin-induced uterine contractions cause primary dysmenorrhea and secondary dysmenorrhea means pelvic pain caused by (secondary to) a disorder or disease.

Dysmenorrhea can create complications such as endometriosis that can cause fertility problems, increasing the risk of a fertilized egg implanting outside of the uterus (ectopic pregnancy), and pelvic inflammatory disease can scar fallopian tubes.

As per the study published in the International Journal of Gynecology & Obstetrics, dysmenorrhea affects more than 80% of women in the reproductive age, and it is the most common gynecological problem worldwide.

Increasing incidence and prevalence of dysmenorrhea and growing awareness regarding dysmenorrhea among females and increasing research and development by companies for developing innovative drugs are the key driving factors in the dysmenorrhea treatment market.

Scope of the Report

Dysmenorrhea also known as menstrual cramps are cramping or throbbing pains in the lower abdomen. Dysmenorrhea treatment market is segmented by treatment type, type, and geography.

By Treatment Type
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Hormonal Therapy
By Type
Primary Dysmenorrhea
Secondary Dysmenorrhea
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Non-Steroidal Anti-Inflammatory Drugs Segment is Expected to Hold a Major Market Share in the Dysmenorrhea Treatment Market

  • Some of the US Food and Drug Administration (FDA) approved NSAIDs for treatment of dysmenorrhea are diclofenac, ibuprofen, ketoprofen, meclofenamate, mefenamic acid, and naproxen.
  • According to the Women's Health Concern and British Menopause Society, about 80% of dysmenorrhea women experience period pain at some stage in their lifetime. Most women experience some discomfort during menstruation, especially on the first day. But in 5%-10% of women, the pain is severe enough to disrupt their life.
  • Moreover, the prevalence of diseases such as endometriosis, which is the leading cause of secondary dysmenorrhea, is also globally.
  • Non-steroidal anti-inflammatory drugs segment holds a significant market share in the dysmenorrhea treatment market. It is anticipated to show a similar trend over the forecast period due to highly effective relieving pain, lower cost, and easy availability of products.
Dysmenorrhea Treatment key trend 1.png

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global dysmenorrhea treatment market due to the increasing incidence and prevalence of dysmenorrhea and awareness of dysmenorrhea among females in this region. As per the study published in the Indian Journal of Research, in the United States, about 2 billion dollars or 600 million working hours are lost annually because of incapacitating dysmenorrhea. Moreover, women who attend classes or work have been shown to have lower work output or scores during their dysmenorrhea. Furthermore, increasing research and development for developing innovative drugs and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Dysmenorrhea Treatment Market 2

Competitive Landscape

The dysmenorrhea treatment market is competitive and consists of several major players. Some of the major players include Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi, Pfizer, Inc, GlaxoSmithKline Plc, Focus Consumer Healthcare, Johnson & Johnson, and Alvogen, among others.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increase In Number ff Women With Dysmenorrhea

      2. 4.2.2 Increasing Research and Development for Developing Innovative Drugs

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects and Complications Associated with Long Term Treatment

      2. 4.3.2 Lack of Awareness About Reproductive Health In Women

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Treatment Type

      1. 5.1.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

      2. 5.1.2 Hormonal Therapy

    2. 5.2 By Type

      1. 5.2.1 Primary Dysmenorrhea

      2. 5.2.2 Secondary Dysmenorrhea

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Novartis AG

      2. 6.1.2 Bayer AG

      3. 6.1.3 Abbott Laboratories

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 Sanofi

      6. 6.1.6 Pfizer Inc

      7. 6.1.7 GlaxoSmithKline Plc

      8. 6.1.8 Focus Consumer Healthcare

      9. 6.1.9 Johnson & Johnson

      10. 6.1.10 Alvogen

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Dysmenorrhea Treatment Market market is studied from 2018 - 2026.

The Dysmenorrhea Treatment Market is growing at a CAGR of 8.1% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Novartis AG, Bayer AG, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Sanofi are the major companies operating in Dysmenorrhea Treatment Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!